• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Renal Cancer Drug Pipeline Update 2014 Product Image

Renal Cancer Drug Pipeline Update 2014

  • Published: July 2014
  • Region: Global
  • Bioseeker

The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being less than 20% (RCC) in this patient cohort.The identification of biomarkers is set to revolutionize patient staging and prognosis by individualizing patient treatments and creating novel drug targets.
There are today 170 companies plus partners developing 208 drugs targeting renal cancer in development. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 77 drugs. Renal Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 205 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 199 out of the 201 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized READ MORE >



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos